Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

PHASE2UnknownINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

Oxaliplatin-based chemotherapy (ESHAOx)

"* Etoposide 40 mg/m2, D1-4~* Methylprednisolone 500mg, D1-5~* Cytarabine 2 g/m2, D5~* Oxaliplatin 130 mg/m2, D1"

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center, Korea, Goyang

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

collaborator

Severance Hospital

OTHER

lead

National Cancer Center, Korea

OTHER_GOV